Autopsy report · NCT00596830
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
Cause of deathNo reason given
“See termination reason in detailed description.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 4 years 5 months before it stopped.
- 681 participants enrolled.
- Results were posted on the registry 1 year 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Pfizer
- Sponsor type
- Industry
- Conditions
- Carcinoma, Squamous Cell; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung
- Interventions
- CP-751,871 (Figitumumab); Carboplatin; Paclitaxel; Carboplatin; Paclitaxel
- Participants
- 681
- Sites
- 280
- Countries
- Australia, Austria, Brazil, Bulgaria, Canada, Czechia, Finland, France, Germany, Greece, Hong Kong, Hungary and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.